Illumina

Youtube Subscribe

Open: 178.31 Close: 175.14 Change: -3.17

10 risks of investing in Illumina Company Inc Stock found by an AI after reading the whole internet.

How much time have you spent trying to decide whether investing in Illumina? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, company, …

Concept Map

Semantic Network

Stock Summary

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company offers sequencing and array-based instruments and consumables, which include reagents, flow.

Today's Summary

Illumina reported flat year-over-year second-quarter revenues, lowered 2023 revenue and earnings per share guidance. Firm was fined 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without commission approval. Steven Barnard, Illuminas Vice President and Head of Global Advanced Science, will serve as Chief Technology Officer.

Today's News

Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Illumina technology had purportedly reduced the cost of sequencing a human genome to US$1,000. Illumina spun off the company Grail in late 2015, focused on blood testing for cancer tumors in the bloodstream. Francis deSouza took on the role of president and CEO. Monib Zirvi filed a lawsuit in the Southern District of New York against Illumina and some of its key employees claiming that they knowingly incorporated ideas and ZipCode DNA sequences invented in the Barany Lab in Illuminas patent applications. The suit was dismissed, only after Illumina claimed that some of those IP misappropriation were “storm warnings” and thus statutes of limitations. Illumina CEO Francis deSouza resigns amid regulatory hurdles, Proxy Fight. CEO expands board after fight with Icahn. Illumina to lay off workers as part of cost cuts. Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates. Shareholders set to vote on Thursday whether to back the gene-sequencing companys incumbent board or named by the commission named by an activist investor. Hedge Funds and institutional investors have recently made changes to their positions in Illumina. SVP Susan H. MD lifted its position in the 4th quarter. The firm has a market cap of $29.27 billion, a P/E ratio. Illumina reported flat year-over-year second-quarter revenues, lowered 2023 revenue and earnings per share guidance. Firm revealed in its quarterly SEC filing that it had received a letter last month informing it of the investigation. Illumina is lowering its 2023 guidance for total revenue and EPS. Firm now anticipates consolidated revenue growth of approximately 1% year over year. Illumina now expects a loss per share of $2.08 to $1.93 and adjusted EPS of $.90. Illumina expects full-year earnings in the range of 75 cents to 90 cents per share. The company is expanding access to genomic technology to realize health equity for billions of people around the world. Illumina stock was rising Thursday, following an initial drop in the premarket session, after the company cut its full-year outlook. The employee data is based on information from people who have self-report their past or current employments at Illumina. Illumina revenue of $1.18 billion and diluted non-GAAP EPS of $0.32, both ahead of guidance we provided in Q1. We are reducing our guidance, and now expect core Illumina full year 2023. Illumina now expects full year 2023 consolidated revenue to grow approximately 1%, including Core Illumina. European Commission imposed €432 million fine on Illumina due to completion of GRAIL acquisition. Illuminas new CTO Steve Barnard joined the company in 1998 as its first scientist and fourth employee. Barnard played an integral role in advancing Illuminas industry-leading products, including the launch of the NovaSeq X series. SEC investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail. Illumina said it is cooperating with the SEC. Last month, the SEC informed Illumina. Steven Barnard, Illuminas Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer. Barnard joined Illumina in 1998 as the companys first scientist and fourth employee. Alex Aravanis, who held the position of CTO, will be departing Illumina. Illumina expects full-year adjusted profit per share to be between $0.75 and $1.90. Steven Barnard, Illuminas Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Citi analyst Patrick Donnelly cut his price target on Illumina to $150. Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023. Illumina was fined 432 million euros ($476 million) for closing its acquisition of Grail without the commissions approval. EU Fines Illumina Record $476 million for Closing Grail Deal Without Approval.

Stock Profile

"Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California."

Keywords

Are looking for the most relevant information about Illumina? Investor spend a lot of time searching for information to make investment decisions in Illumina. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, company, revenue, Illuminas, expect, Barnard, Grail, and the most common words in the summary are: illumina, job, inc, stock, grail, company, sequence, . One of the sentences in the summary was: Illumina reported flat year-over-year second-quarter revenues, lowered 2023 revenue and earnings per share guidance. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #illumina #job #inc #stock #grail #company #sequence.

Read more →

Youtube Subscribe

---